Confirm anti er sp1

Manufactured by Roche

Sourced in Japan

The CONFIRM anti‐ER [SP1] is a laboratory equipment product manufactured by Roche. It is used for the detection and quantification of estrogen receptor (ER) in human breast cancer tissue samples. The product functions by providing an automated and standardized method for the analysis of ER expression levels, which is a crucial biomarker in the diagnosis and management of breast cancer.

Automatically generated - may contain errors

Lab products found in correlation

Herceptest, by Agilent Technologies (4 mentions) Ventana benchmark xt, by Roche (4 mentions) Confirm anti pr 1e2, by Roche (3 mentions) Histofine kit, by Nichirei Biosciences (2 mentions) Mib 1, by Thermo Fisher Scientific (1 mentions) Ki 67 mib 1, by Agilent Technologies (1 mentions) Benchmark ultra platform, by Roche (1 mentions) Ls b243, by LSBio (1 mentions) Ab96280, by Abcam (1 mentions) Mib 1, by Agilent Technologies (1 mentions)

5 protocols using confirm anti er sp1

Immunohistochemical Analysis of CYC1, ER, PR, and HER2

Check if the same lab product or an alternative is used in the 5 most similar protocols

Rabbit polyclonal antibody for CYC1 (PA5‐25257) and mouse mAb for Ki‐67 (MIB1) were purchased from Thermo Fisher Scientific (Waltham, MA, USA) and Dako (Carpinteria, CA, USA), respectively. The antigen–antibody complex was visualized with DAB solution and counterstained with hematoxylin. We used human tissue of the stomach as a positive control based on a data sheet of CYC1 antibody by Novus Biologicals (http://www.novusbio.com/CYC1-Antibody_NBP1-86872.html#dsTab0) and normal rabbit IgG instead of the primary antibody as a negative control for CYC1 immunostaining in this study.
Immunohistochemistry for ER (CONFIRM anti‐ER [SP1]; Roche Diagnostics Japan, Tokyo, Japan) and PR (CONFIRM anti‐PR [1E2]; Roche Diagnostics Japan) was carried out with Ventana Benchmark XT (Roche Diagnostics Japan), and that for HER2 was carried out using HercepTest (Dako).

Chishiki M., Takagi K., Sato A., Miki Y., Yamamoto Y., Ebata A., Shibahara Y., Watanabe M., Ishida T., Sasano H, & Suzuki T. (2017). Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. Cancer Science, 108(7), 1510-1519.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Breast Cancer Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Rabbit polyclonal antibody for TACC2 (GTX110516) and mouse monoclonal antibodies for Ki‐67 (MIB1) and androgen receptor (AR; AR441) were purchased from Gene Tex (Hsinchu, Taiwan ROC), DAKO (Carpinteria, CA) and DAKO, respectively. A Histofine Kit (Nichirei Biosciences, Tokyo, Japan), which employs the method of streptavidin‐biotin amplification was used in this study. The visualization of antigen–antibody complex was possible with 3,3′‐diaminobenzidine (DAB) solution and after that counterstained with hematoxylin. As a positive control for TACC2 immunostaining, human prostate carcinoma tissue was used 10. Immunohistochemistry for estrogen receptor (ER) (CONFIRM anti‐ER (SP1)) and progesterone receptor (PR) (CONFIRM anti‐PR (1E2); Roche Diagnostics, Tokyo, Japan) was performed with Ventana Benchmark XT (Roche Diagnostics), and that for HER2 was performed by HercepTest (DAKO). Ki‐67 (MIB1) was purchased from DAKO, and a Histofine Kit (Nichirei Bioscience, Tokyo, Japan) was used for the immunohistochemistry.

Onodera Y., Takagi K., Miki Y., Takayama K., Shibahara Y., Watanabe M., Ishida T., Inoue S., Sasano H, & Suzuki T. (2016). TACC2 (transforming acidic coiled‐coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation. Cancer Medicine, 5(8), 1973-1982.

+ Open protocol

+ Expand

Standardized ER Assessment of Liver Metastases

Check if the same lab product or an alternative is used in the 5 most similar protocols

According to standard clinical care procedures, all ultrasound-guided percutaneous 18G core needle liver biopsies were performed by experienced abdominal radiologists. ER status of the liver metastasis was determined by staining the formalin-fixed paraffin-embedded liver biopsies using the CONFIRM anti-ER (SP1, Roche) on an automated Benchmark Ultra platform (Roche). Metastases were deemed ER+ if ≥10% of the tumor cells showed nuclear staining, according to Dutch guidelines. The immunohistochemical evaluation of the ER status was used as the reference standard.

Boers J., Loudini N., de Haas R.J., Willemsen A.T., van der Vegt B., de Vries E.G., Hospers G.A., Schröder C.P., Glaudemans A.W, & de Vries E.F. (2021). Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer. Diagnostics, 11(11), 2019.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mouse monoclonal antibodies for CITED2 (LS‐B243) and Ki‐67 (MIB1) were purchased from LSBio (Seattle, WA, USA) and Dako (Carpinteria, CA, USA), respectively. The antigen–antibody complex was visualized with 3,3′‐diaminobenzidine solution and counterstained with hematoxylin. Immunohistochemistry for ER (CONFIRM anti‐ER [SP1]) and progesterone receptor (PR) (CONFIRM anti‐PR [1E2]; Roche Diagnostics Japan, Tokyo, Japan) was performed with Ventana Benchmark XT (Roche Diagnostics Japan), and that for HER2 was performed by HercepTest (Dako).

Minemura H., Takagi K., Sato A., Takahashi H., Miki Y., Shibahara Y., Watanabe M., Ishida T., Sasano H, & Suzuki T. (2016). CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. Cancer Science, 107(12), 1898-1908.

+ Open protocol

+ Expand

Immunohistochemical Evaluation of Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Rabbit polyclonal antibodies for OLFM4 (ab96280) and LY6D (HPA024755) and mouse monoclonal antibody for S100A7 (47C1068) were purchased from Abcam (Cambridge, UK), Sigma‐Aldrich (St. Louis, MO, USA) and LifeSpan BioSciences (Seattle, WA, USA), respectively. Immunostaining for these 3 antibodies was automatically performed using Ventana Benchmark XT platform (Roche Diagnostics Japan, Tokyo, Japan). As a positive control, we used human tissue of the prostate, skin and skin for OLFM4, LY6D and S100A7, respectively, based on the data sheet (OLFM4) and database of the Human Protein Atlas (https://www.proteinatlas.org) (LY6D and S100A7).
Immunohistochemistry for ER (CONFIRM anti‐ER [SP1]) and progesterone receptor (PR) (CONFIRM anti‐PR [1E2]; Roche Diagnostics Japan) was also performed with Ventana Benchmark XT (Roche Diagnostics Japan), and that for HER2 was performed by HercepTest (DAKO). Mouse monoclonal antibody for Ki67 (MIB1) was purchased from DAKO (Carpinteria, CA, USA), and a Histofine kit (Nichirei Bioscience, Tokyo, Japan) was used for the immunohistochemistry.

Mayama A., Takagi K., Suzuki H., Sato A., Onodera Y., Miki Y., Sakurai M., Watanabe T., Sakamoto K., Yoshida R., Ishida T., Sasano H, & Suzuki T. (2018). OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor‐positive breast carcinoma. Cancer Science, 109(10), 3350-3359.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!